CD20

Assets acting on this target.

Class
Anti-CD20 monoclonal antibody
Pathway
B-cell depletion

CD20 is a cell-surface protein expressed on B lymphocytes, a class of white blood cells responsible for producing antibodies and, in some diseases, for driving damaging immune activity. CD20 appears at a defined stage of B-cell development and is retained on most mature B cells, but it is absent from the earliest precursor cells and from the plasma cells that ultimately secrete antibodies. This expression pattern makes it an attractive target: antibodies directed against CD20 can eliminate the pool of circulating and tissue-resident B cells implicated in disease while sparing the stem-cell compartment needed to regenerate the immune system and largely sparing long-lived plasma cells. Depleting B cells interrupts several disease-relevant processes, including production of harmful autoantibodies, presentation of antigens to other immune cells, and secretion of inflammatory signaling molecules. This rationale underlies the use of anti-CD20 antibodies across B-cell malignancies, where the target cells are themselves the tumor population, and across autoimmune conditions such as those affecting the nervous system or joints, where B cells contribute to disease even though they are not cancerous. Because CD20 does not shed from the cell surface or circulate freely in blood, it remains a stable, accessible target for antibody binding throughout treatment.

By indication

Related mechanisms

CD20 drugs compared

16 drugs, stage by indication
16 drugs acting on CD20: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
ObinutuzumabRochemonoclonal antibodyApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Follicular Lymphoma; Approved in Lupus Nephritis; Approved in Primary Membranous Nephropathy; Phase 3 in Non-Hodgkin Lymphoma
OcrelizumabRochemonoclonal antibodyApprovedApproved in Multiple Sclerosis
Ocrevus ZunovoRochemonoclonal antibody + enzymeApprovedApproved in Multiple Sclerosis
OfatumumabNovartismonoclonal antibodyApprovedApproved in Multiple Sclerosis
PF-05280586Pfizerbiologic (registry-typed, subtype undisclosed)ApprovedApproved in B-Cell Non-Hodgkin Lymphoma; Approved in Chronic Lymphocytic Leukemia; Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Large B-Cell Lymphoma; Approved in Non-Hodgkin Lymphoma; Approved in Relapsed/Refractory Non-Hodgkin Lymphoma; Approved in Rheumatoid Arthritis
RituximabRituxanBiogen, Chugai Pharma, Roche, Zenyaku Kogyomonoclonal antibodyApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Diffuse Large B-Cell Lymphoma; Approved in Follicular Lymphoma; Approved in Rheumatoid Arthritis
Rituximab-abbs (Truxima)TruximaCelltrion, Teva Pharmaceutical Industriesmonoclonal antibodyApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Non-Hodgkin Lymphoma; Approved in Rheumatoid Arthritis
UblituximabBriumviNeuraxpharm, TG THERAPEUTICS, INC.monoclonal antibodyApprovedApproved in Multiple Sclerosis; Phase 2 in Myasthenia Gravis; Phase 2 in Schizophrenia
ABP 692Amgenmonoclonal antibodyPhase 3Phase 3 in Multiple Sclerosis
AcellbiaBiocadmonoclonal antibodyPhase 3Phase 3 in Rheumatoid Arthritis
BCD-281Biocadmonoclonal antibodyPhase 3Phase 3 in Multiple Sclerosis
CT-P53Celltrionmonoclonal antibodyPhase 3Phase 3 in Multiple Sclerosis
DivozilimabIvliziBiocadmonoclonal antibodyPhase 3Phase 3 in Multiple Sclerosis; Phase 3 in Systemic Sclerosis; Phase 1 in Systemic Lupus Erythematosus
HLX01HanlikangShanghai Henlius Biotechmonoclonal antibodyPhase 3Phase 3 in Rheumatoid Arthritis
Obinutuzumab beta (Bejescin)BejescinBeijing Mabworks Biotech Co., Ltd., Everest Medicines (Beijing) Co., Ltd.monoclonal antibodyPhase 3Phase 3 in Follicular Lymphoma; Phase 3 in Primary Membranous Nephropathy; Phase 3 in Systemic Lupus Erythematosus
SAR448501Sanofibispecific antibodyPhase 1Phase 1 in Rheumatoid Arthritis; Phase 1 in Systemic Lupus Erythematosus

← all mechanisms